TocilizuMab discontinuAtion in GIant Cell Arteritis

PHASE3RecruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

May 13, 2024

Primary Completion Date

December 31, 2027

Study Completion Date

November 30, 2028

Conditions
Giant Cell Arteritis
Interventions
DRUG

Tocilizumab treatment

"* 1 injection/2 weeks from W0 to W12: W0, W2, W4, W6, W8, W10, W12~* Then 1 injection/4 weeks until W24: W16, W20, W24"

OTHER

questionnaires

HAQ, SF-36, FACIT-Fatigue score

BIOLOGICAL

Blood samples

Additionnal blood samples for immunomonitoring

PROCEDURE

18FDG PET scan

PETVAS calculation (to be performed between W0 and W8) (optional).

Trial Locations (1)

21000

RECRUITING

Chu Dijon Bourgogne, Dijon

All Listed Sponsors
lead

Centre Hospitalier Universitaire Dijon

OTHER